Daily evidence update
DAILY UPDATE ·
Daily microbiome literature · 14 October 2026
A clinical intervention during platinum-based chemotherapy and a single-arm pilot in perimenopausal women reported gastrointestinal and hormonal outcomes with important design and reporting limits.
- Papers
- 58
- Within scope
- 53
- Primary human interventions
- 2
- Studies included
- 2
Daily microbiome literature · 14 October 2026
Probiotic intervention during platinum-based chemotherapy
Microbiome-based probiotic intervention to reduce chemotherapy-induced gastrointestinal toxicity.
A clinical intervention enrolled 150 patients receiving platinum-based chemotherapy and used Lactobacillus casei; dose not reported in the abstract, and the intervention duration was not reported in the abstract. overall gastrointestinal toxicity was lower with probiotic supplementation than control; 85% of control patients compared with 65% of probiotic-treated patients. diarrhea was less frequent with probiotic supplementation than control; 60% of control patients compared with 35% of probiotic-treated patients. grade 3-4 gastrointestinal toxicity was lower with probiotic supplementation than control; 40% of control patients compared with 20% of probiotic-treated patients. the incidence of mucositis was lower with probiotic supplementation than control; effect estimate not reported in the abstract. the severity of mucositis was lower with probiotic supplementation than control; effect estimate not reported in the abstract. the incidence of nausea was lower with probiotic supplementation than control; effect estimate not reported in the abstract. the severity of nausea was lower with probiotic supplementation than control; effect estimate not reported in the abstract. the incidence of vomiting was lower with probiotic supplementation than control; effect estimate not reported in the abstract. the severity of vomiting was lower with probiotic supplementation than control; effect estimate not reported in the abstract. gut microbial dysbiosis after chemotherapy was less pronounced with probiotic supplementation than control; effect estimate not reported in the abstract.
Probiotic pilot in perimenopausal women
A single-arm pre-post pilot enrolled 20 perimenopausal women aged 50–55 years who received 10^9 colony-forming units/day of probiotics (Lactobacillus acidophilus, Lactobacillus rhamnosus and Bifidobacterium longum) for 12 weeks. estradiol increased after probiotic supplementation; increase in estradiol of 6.86 ±-5.20 pg/ml.
Today's literature: 58 papers; 2 primary human interventions. 5 animal and in-vitro studies read, not shown.
Microbiome-based probiotic intervention to reduce chemotherapy-induced gastrointestinal toxicity.
STUDY DESCRIPTORCLINICAL INTERVENTION
Model: human participants.MODEL · HUMAN PARTICIPANTS
INTERPRETATION BOUNDARY
Data from human participants do not by themselves establish applicability beyond the population and outcomes studied. The abstract did not report random assignment. The probiotic dose and intervention duration were not reported in the abstract. Treatment response did not differ significantly between groups.
SOURCEPMID 42871065
Modulation of hormones in perimenopausal women by probiotics associated by specific gut bacteria: a pilot study.
STUDY DESCRIPTORSINGLE-ARM PILOT
Model: human participants.MODEL · HUMAN PARTICIPANTS
INTERPRETATION BOUNDARY
Data from human participants do not by themselves establish applicability beyond the population and outcomes studied. This single-arm pilot had no concurrent control group. The probiotic dose was printed as ‘10^9 colony-forming units/day’; the exponent could not be recovered. The abstract stated that methodological limitations prevented demonstrating a direct impact on quality of life.
SOURCEPMID 42871936
ISSUE INTERPRETATION BOUNDARY
This dated record covers two included human studies from 58 papers found; 53 were within scope and 11 were reviewed. It is not a complete bibliography of the day.